Work

Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma

Year: 2019

Type: article

Abstract: Flavopiridol (alvocidib) is a semi-synthetic flavon which inhibits cyclin-dependent kinases (CDKs) 1, 2, and 4 by outcompeting adenosine triphosphate (ATP), and CDK7 and CDK9 by non-competitive bin...

Source: Leukemia & lymphoma/Leukemia and lymphoma

DOI: 10.1080/10428194.2019.1627540

Authors: Milos D. Miljkovic, Mark Roschewski, Kieron Dunleavy, Wyndham H. Wilson

Institutions: National Cancer Institute, Center for Cancer Research, George Washington University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: Phase II study of flavopiridol in mantle cell lymphoma and DLBCL, G9000058274

OpenAlex ID: W2953096157

FWCI: 0.313

Cites: 15

Cited by: 4

Related to: 10